Diffusion of Minimally Invasive Approach for Lung Cancer Surgery in France: A Nationwide, Population-Based Retrospective Cohort Study.
lung cancer surgery
minimally invasive approach
region
variation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Jun 2023
22 Jun 2023
Historique:
received:
15
05
2023
revised:
20
06
2023
accepted:
20
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
The minimally invasive approach (MIA) has gained popularity thanks to its efficacy and safety. Our work consisted of evaluating the diffusion of the MIA in hospitals and the variability of this approach (within and between regions). All patients who underwent limited resection or lobectomy for lung cancer in France were included from the national hospital administrative database (2013-2020). We described between-hospital differences in the MIA rate over four periods (2013-2014, 2015-2016, 2017-2018, and 2019-2020). The potential influence of the hospital volume, hospital type, and period on the adjusted MIA rate was estimated by a multilevel linear regression. From 2013 to 2020, 77,965 patients underwent a lobectomy or limited resection for lung cancer. The rate of the MIA increased significantly over the four periods (50% in 2019-2020). Variability decreased over time in 7/12 regions. The variables included in the multilevel model were significantly related to the adjusted rate of the MIA. Variability between regions was considerable since 18% of the variance was due to systematic differences between regions. We confirm that the MIA is part of the surgical techniques used on a daily basis for the treatment of lung cancer. However, this technology is mostly used by surgeons in high volume institutions.
Sections du résumé
BACKGROUND
BACKGROUND
The minimally invasive approach (MIA) has gained popularity thanks to its efficacy and safety. Our work consisted of evaluating the diffusion of the MIA in hospitals and the variability of this approach (within and between regions).
METHODS
METHODS
All patients who underwent limited resection or lobectomy for lung cancer in France were included from the national hospital administrative database (2013-2020). We described between-hospital differences in the MIA rate over four periods (2013-2014, 2015-2016, 2017-2018, and 2019-2020). The potential influence of the hospital volume, hospital type, and period on the adjusted MIA rate was estimated by a multilevel linear regression.
RESULTS
RESULTS
From 2013 to 2020, 77,965 patients underwent a lobectomy or limited resection for lung cancer. The rate of the MIA increased significantly over the four periods (50% in 2019-2020). Variability decreased over time in 7/12 regions. The variables included in the multilevel model were significantly related to the adjusted rate of the MIA. Variability between regions was considerable since 18% of the variance was due to systematic differences between regions.
CONCLUSIONS
CONCLUSIONS
We confirm that the MIA is part of the surgical techniques used on a daily basis for the treatment of lung cancer. However, this technology is mostly used by surgeons in high volume institutions.
Identifiants
pubmed: 37444392
pii: cancers15133283
doi: 10.3390/cancers15133283
pmc: PMC10339983
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Oncol. 2016 Jun;17(6):836-844
pubmed: 27160473
Lancet Respir Med. 2021 Mar;9(3):251-259
pubmed: 33341155
Ann Surg. 2023 Mar 1;277(3):528-533
pubmed: 34534988
Ann Cardiothorac Surg. 2023 Jan 31;12(1):1-8
pubmed: 36793987
Br J Surg. 2023 Mar 30;110(4):441-448
pubmed: 36724824
Thorac Surg Clin. 2008 Aug;18(3):235-47
pubmed: 18831498
Arch Bronconeumol (Engl Ed). 2020 Jan;56(1):23-27
pubmed: 31138446
Interact Cardiovasc Thorac Surg. 2019 Apr 1;28(4):526-534
pubmed: 30496420
Ann Surg. 2017 Feb;265(2):431-437
pubmed: 28059973
J Pers Med. 2023 Jan 21;13(2):
pubmed: 36836426
J Thorac Dis. 2018 Oct;10(10):5685-5694
pubmed: 30505476
Ann Surg. 2018 Aug;268(2):254-259
pubmed: 28628562
Circulation. 2020 Oct 6;142(14):1351-1360
pubmed: 33017214
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Eur Respir J. 2021 Aug 19;58(2):
pubmed: 33479108
Cancers (Basel). 2021 Dec 14;13(24):
pubmed: 34944896
Stroke. 2021 Apr;52(4):1362-1369
pubmed: 33626900
World J Surg Oncol. 2017 May 8;15(1):98
pubmed: 28482928
Health Technol Assess. 2022 Dec;26(48):1-162
pubmed: 36524582
BMJ Open. 2023 Mar 7;13(3):e068145
pubmed: 36882257
Semin Thorac Cardiovasc Surg. 2018 Autumn;30(3):350-359
pubmed: 29549015
Eur J Cardiothorac Surg. 2019 Oct 01;56(4):754-761
pubmed: 30838382
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Psychiatry Res. 2023 Jun;324:115214
pubmed: 37084571
Am J Obstet Gynecol. 2023 Mar 17;:
pubmed: 36935070
Ann Oncol. 2021 Dec;32(12):1637-1642
pubmed: 34481037
Int J Clin Exp Med. 2015 Oct 15;8(10):17804-10
pubmed: 26770372
Front Med (Lausanne). 2023 Mar 14;10:1110977
pubmed: 36999073
J Thorac Dis. 2018 Aug;10(8):4764-4773
pubmed: 30233848
Ann Oncol. 2014 Aug;25(8):1462-74
pubmed: 24562446
Eur Respir J. 2016 Jun;47(6):1809-17
pubmed: 26965293
Ann Thorac Surg. 2020 Mar;109(3):848-855
pubmed: 31689407
PLoS One. 2019 Jul 24;14(7):e0219672
pubmed: 31339906
J Thorac Cardiovasc Surg. 2019 May;157(5):2038-2046.e1
pubmed: 31288364